Retatrutide vs Survodutide
Both compounds engage the glucagon receptor, which links them in metabolic research. The difference is breadth: survodutide is a GLP-1/glucagon dual agonist, while retatrutide adds GIP to become a triple agonist.
| Retatrutide | Survodutide | |
|---|---|---|
| Compound class | Triple GIP/GLP-1/glucagon agonist | Dual GLP-1/glucagon receptor agonist |
| Primary target | GIP + GLP-1 + glucagon receptors | GLP-1 + glucagon receptors |
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Administration | Weekly subcutaneous | Weekly subcutaneous |
| Research focus | Energy expenditure & metabolic endpoints | Metabolic & hepatic (MASH) research |
Key differences
- Receptor breadth: survodutide hits GLP-1 + glucagon; retatrutide hits GIP + GLP-1 + glucagon.
- Research emphasis: survodutide features prominently in hepatic/MASH research, while retatrutide is studied broadly for metabolic and energy-expenditure endpoints.
- Both leverage glucagon agonism, so they share that mechanistic theme more than most GLP-1 compounds.
- Both are weekly subcutaneous compounds titrated from low starting doses.
Which is right for your research?
Survodutide is the focused GLP-1/glucagon dual agonist (notably in liver research); retatrutide is the broader triple agonist when GIP coverage also matters.
Frequently asked questions
Do retatrutide and survodutide both target glucagon?
Yes. Both activate the glucagon receptor. Retatrutide additionally activates GIP, making it a triple agonist versus survodutide's dual agonism.
What is survodutide most studied for?
Survodutide appears prominently in hepatic and metabolic (MASH) research alongside its weight-related endpoints.
Are they dosed similarly?
Both are weekly subcutaneous compounds that titrate from low starting doses.
For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.